Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT03492489
- Status
- No Longer Available
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- cemiplimab — DRUGIntravenous (IV) administration
Study Details
The objective of this program is to provide access to cemiplimab (REGN2810) to patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for surgery prior to cemiplimab (REGN2810) being commercially available.
Key Dates
- Status verified
- Jul 2019
Related Studies
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · Recruiting · Bicara Therapeutics · La Jolla, California
- Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaPHASE1 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsPHASE1 · Recruiting · Memgen, Inc. · Tampa, Florida
- A Beta-only IL-2 ImmunoTherapY StudyPHASE1/PHASE2 · Recruiting · Medicenna Therapeutics, Inc. · San Diego, California